404
+1-313-307-4176
sales@stratviewresearch.com
D Dimer Testing Market Report
D-dimer Testing Market Size, Share, Trend, Forecast, & Industry Analysis: 2021-2026
D-dimer Testing Market, By Test Type (Clinical Laboratory Tests, Point-of-Care Tests), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular Coagulation (DIC), Others), and Region - COVID-19 Impact Analys...
D-dimer testing is blood tests that are performed to measure the blood ability & clotting disorder. These tests are primarily consulted by doctors, during suspicion of a clotting disorder or for the diagnosis of hemostasis system. D-Dimer is a protein fragment that has two cross-linked D fragments of protein known as fibrin that is found in a human blood sample after degradation of the blood clot by fibrinolysis. D-dimer testing is primarily used for the diagnosis of pulmonary embolism, deep vein thrombosis (DVT), and disseminated intravascular coagulation (DIC). These tests are conducted to identify the presence of D-dimer in the blood and locate any chronic clots in the body. These tests involve the emergence of monoclonal anti-D-dimer bodies with latex particles, which improves the molecular weight of the immunocomplexes in the test sample.
The D-dimer Testing Market is estimated to grow from USD 1.4 billion in 2020 to USD 1.8 billion by 2026 at a healthy CAGR of 4.5% during the forecast period.
|
D-dimer Testing Market- Research Scope |
|
|---|---|
|
Base Year of Study |
2020 |
|
Trend Period |
2015-2019 |
|
Forecast Period |
2021-2026 |
|
Market Size in 2020 |
US$ 1.4 billion |
|
Market Size in 2026 |
US$ 1.8 billion |
|
Market Growth (2021-2026) |
4.5% CAGR |
The D-dimer Testing market is mainly driven by a significant shift towards the demand for next-generation point-of-care D-dimer testing. This is mainly due to the implementation of POC solutions substantially lowering waiting time, enabling faster diagnosis, reducing the length of patient stay, and leading to improved patient experience. The benefits gained from these solutions in POC settings as well as the rising incidence rate of Venous Thromboembolism (VTE) along with several pulmonary & cardiovascular diseases, which causes life-threatening issues owing to blood clot formation is increasing the demand for D-dimer testing, thus augmenting the market growth.
The outbreak of COVID-19 moderately affected the D-dimer testing industry. The healthcare industry is currently facing major challenges as it is unable to provide proper medical facilities to meet the ever-growing coronavirus patient pool. With the stringent imposition of lockdown and social distance regulations, there were limited testing and appointments for blood clots, thus affecting the market growth.
Based on test type, the D-dimer Testing market has been divided into clinical laboratory tests and point-of-care tests. The clinical laboratory tests segment accounted for the largest market share of over 60% in 2020. Highly sensitive D-dimer assays are generally used for the exclusion of VTE as well as for the management of disseminated intravascular coagulation. Clinical laboratories have a higher frequency of tests and are well-equipped with medical facilities, thereby augmenting the segment growth.
By region, the North American D-dimer Testing market accounted for the largest share of more than 32% in 2020 and is expected to grow at a significant CAGR during the review period. The D-dimer Testing market growth is mainly propelled by well-equipped healthcare infrastructure, highly qualified medical professionals, rising prevalence of blood clots in patients in the region, and increasing healthcare expenditure, further bolstering the regional market growth.
The Asia-Pacific D-dimer Testing market is expected to grow at the highest CAGR during the review on account of the growth of the major end-use industries. This growth is mainly attributed to the presence of a large patient pool in the developing economies of China and India. Also, the presence of supportive guidelines for coagulation tests laid down by the private organizations & government bodies coupled with surging funds for healthcare facilities further proliferate the regional market expansion.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global D-dimer testing market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026. Following are the critical questions answered in the report.
Key players operating in the D-dimer Testing Market are-
The target audience of D-dimer Testing Market includes-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.
The D-dimer testing market is expected to witness an impressive growth of 4.5% CAGR in the coming years.
Laboratory Corporation of America Holdings (US), Response Biomedical Corp (Canada), Unbound Medicine, Inc (US), Helena Laboratories (US), Siemens Healthcare Diagnostics (US), Trinity Biotech plc (Ireland), Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories, Inc (US), Eurolyser Diagnostica GmbH (Austria), ARUP Laboratories (US) are among the key players in the D-dimer testing market.
The D-dimer testing market size is expected to reach USD 1.8 billion in the foreseeable future.
The clinical laboratory tests segment accounted for the largest share in the D-dimer testing market in 2020.
North America accounted for the largest share in the D-dimer testing market in 2020.
D-dimer Testing Vendors, D-dimer Testing Manufacturers, D-dimer Testing Distributors, Organizations, Government Bodies are the target audience in the D-dimer testing market.
WE ACCEPT
